Maiva Pharma, a contract development and manufacturing Oorganisation (CDMO) for North America, on Thursday said it has raised Rs 1,000 crore in primary and secondary funding from a fund managed by Morgan Stanley Private Equity Asia and India Life Sciences Fund IV.
Continue Reading: Unlock Free Insights!
Stay updated with 3 free articles every month
Access our exclusive newsletters delivered to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
